MENU
+Compare
LYRA
Stock ticker: NASDAQ
AS OF
Dec 26, 04:59 PM (EDT)
Price
$0.18
Change
+$0.01 (+5.88%)
Capitalization
11.28M

LYRA Lyra Therapeutics Forecast, Technical & Fundamental Analysis

a clinical-stage therapeutics company, which develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases

Industry Biotechnology
LYRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for LYRA with price predictions
Dec 24, 2024

LYRA in upward trend: price expected to rise as it breaks its lower Bollinger Band on December 18, 2024

LYRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 37 cases where LYRA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LYRA's RSI Oscillator exited the oversold zone, of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where LYRA advanced for three days, in of 219 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 13, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on LYRA as a result. In of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for LYRA turned negative on December 17, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LYRA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for LYRA entered a downward trend on November 27, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.547) is normal, around the industry mean (18.292). P/E Ratio (0.000) is within average values for comparable stocks, (87.498). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.756). LYRA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (7.513) is also within normal values, averaging (260.038).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. LYRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LYRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
LYRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

LYRA is expected to report earnings to rise 6.94% to -19 cents per share on March 05

Lyra Therapeutics LYRA Stock Earnings Reports
Q4'24
Est.
$-0.19
Q3'24
Beat
by $0.04
Q2'24
Missed
by $0.41
Q1'24
Missed
by $0.09
Q4'23
Beat
by $0.13
The last earnings report on November 12 showed earnings per share of -18 cents, beating the estimate of -21 cents. With 943.62K shares outstanding, the current market capitalization sits at 11.28M.
A.I. Advisor
published General Information

General Information

a clinical-stage therapeutics company, which develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
480 Arsenal Way
Phone
+1 617 393-4600
Employees
145
Web
https://lyratherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OLB1.680.03
+1.82%
OLB Group Inc. (The)
NICE175.421.75
+1.01%
NICE Ltd
MQ3.700.03
+0.82%
Marqeta
CCO1.390.01
+0.72%
Clear Channel Outdoor Holdings
ACU36.95-0.04
-0.11%
Acme United Corp

LYRA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, LYRA has been closely correlated with GLYC. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if LYRA jumps, then GLYC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LYRA
1D Price
Change %
LYRA100%
-1.49%
GLYC - LYRA
75%
Closely correlated
+11.78%
EYPT - LYRA
60%
Loosely correlated
+1.10%
SQZB - LYRA
29%
Poorly correlated
N/A
BCYC - LYRA
27%
Poorly correlated
+1.03%
ARVN - LYRA
26%
Poorly correlated
+4.06%
More

Groups containing LYRA

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LYRA
1D Price
Change %
LYRA100%
-1.49%
LYRA
(2 stocks)
94%
Closely correlated
+3.17%